Effective Deal Making in Drug Delivery

Published by	PharmaVentures Ltd
Published	January, 2009	Product code	89955
Content info	142 Pages
Price	US $ 5993 Hard Copy US $ 8990 PDF BY E-mail

Introduction
Related Reports

Effective Deal Making in Drug Delivery published by PharmaVentures Ltd in January, 2009. This report consists of 142 Pages and the price starts from US $ 5993.

Introduction

Abstract

“Looming patent expiry a major force in driving valuation”

Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commerical viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new PharmaDealsR Report, covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

1. Introduction

2. Market Overview

2.1 Types of Drug Delivery
2.2 Development of the Drug Delivery Market
2.3 The Current and Evolving Market
2.4 Future Market Challenges
2.5 Drug Delivery Companies
- 2.5.1 Principal Players in Drug Delivery
- 2.5.2 The Changing Landscape: M&A Activity
- 2.5.3 The True Scope of the Drug Delivery Sector

3. Key Drivers in Drug Delivery

3.1 Improving the Therapeutic Index
3.2 Patient Compliance
3.3 Patent Prolongation
3.4 Life Cycle Management

4. Commercialisation Strategies

4.1 Introduction
4.2 Returns to Innovation
4.3 Drug Delivery Product Offerings
4.4 Exploitation Strategies
4.5 Business Models
4.6 Product, Strategy and Business Models for Drug Delivery Technology
4.7 Applicability to Segments of the Pharmaceutical Product Life Cycle
4.8 Assessment of Attractiveness of Each Option
- 4.8.1 Divestment to a Service-Based Company
- 4.8.2 Licensing to Pharmaceutical Companies
- 4.8.3 Sales of Devices
- 4.8.4 Service Offering
- 4.8.5 Development of Drugs in Collaboration with other Companies
- 4.8.6 In-House Drug Development
4.9 Compatibility of Product Offerings
4.10 Conclusion

5. Alliances in Drug Delivery

5.1 Drug Delivery Deals Database
5.2 Drug Delivery Deal Activity
5.3 Financial Analysis of Drug Delivery Deals

6. Major Pharmaceutical Company Drug Delivery Deal Activity

6.1 Johnson & Johnson
6.2 Pfi zer
6.3 GlaxoSmithKline (GSK)
6.4 Novartis
6.5 Sanofi -aventis
6.6 Roche
6.7 AstraZeneca
6.8 Merck & Co
6.9 Abbott Laboratories
6.10 Wyeth

7. Valuation Methods

7.1 Integrated Benchmarking and ENPV Calculation
7.2 Other Methods
7.3 Benchmarking
- 7.3.1 Feasibility Search
- 7.3.2 Information Gathering and Analysis
- 7.3.3 Approximate Valuation
- 7.3.4 Refi nement of Valuation
7.4 Expected Net Present Value
7.5 Agreement Structure
- 7.5.1 Value Sharing
- 7.5.2 Risk Sharing
7.6 Valuation of Drug Delivery Systems
- 7.6.1 Enabling Technology
- 7.6.2 Enhancing Technology

8. Drug Delivery Alliance Development Process

8.1 Needs Identifi cation
- 8.1.1 Driving Factors
  - 8.1.1.1 Market Drivers
  - 8.1.1.2 Technology Drivers
- 8.1.2 Tools Needs Identifi cation
  - 8.1.2.1 Portfolio Analysis
  - 8.1.2.2 Value Chain Analysis
8.2 Identifying Opportunities and Partners
8.3 Development of Commercial Relationships

9. Drug Delivery Agreements

Table of drug delivery agreements linked to the PharmaDeals® v2 Agreements Database

Tables

1. Typical maximum doses per administration
2. Marketed recombinant biopharmaceuticals among the top 200 selling prescription drugs
3. Publicly quoted specialty pharmaceutical companies that focus on drug delivery
4. Elan' s partnering activity
5. Major patent expirations, 2008 - 2012
6. Strategies for the exploitation of innovation
7. Business models
8. Generic strategies for commercialisation
9. Product offerings and target segments
10. Compatibility of product offerings
11. Number of drug delivery deals by therapeutic area, 1997 - October 2008
12. Number of drug delivery deals by product type, 1997 - October 2008
13. Average total deal values for drug delivery deals, 1997 - October 2008
14. Average upfront payments for drug delivery deals, 1997 - October 2008
15. Average milestone payments for drug delivery deals, 1997 - October 2008
16. Average equity investment payments for drug delivery deals, 1997 - October 2008
17. Top ten pharmaceutical companies by 2007 worldwide healthcare revenue
18. Johnson & Johnson drug delivery deals
19. Alza drug delivery deals (part of Johnson & Johnson)
20. Pfizer drug delivery deals
21. Pharmacia drug delivery deals
22. GlaxoSmithKline drug delivery deals
23. Novartis drug delivery deals
24. Sanofi-aventis drug delivery deals
25. Roche drug delivery deals
26. AstraZeneca drug delivery deals
27. Abbott drug delivery deals
28. Merck & Co. drug delivery deals
29. Wyeth drug delivery deals
30. Benchmarking methodology overview
31. Sources of information
32. Cumulative probabilities
33. Example ENPV calculation
34. Pharmaceutical industry event calendars
35. Key factors leading to successful alliances between companies
36. Drug delivery agreements linked to PharmaDeals

Figures

1. Pharmaceutical company R&D drug delivery projects by route of delivery
2. Drug delivery mergers and acquisitions, 1997 - 2008
3. Effect of controlled release formulations
4. Doses of chemotherapeutic agent required to achieve maximum effect
5. Estimated value in 2008 worldwide sales of the top 200 prescription drugs by year of US patent expiry
6. Life cycle management
7. All deal activity, 1997 - 2008
8. Drug delivery deal activity, 1997 - 2008
9. All deals according to deal type, 1997 - 2008
10. Drug delivery deals according to deal type, 1997 - 2008
11. Number of drug delivery deals by therapeutic area, 1997 - 2008
12. Number of drug delivery deals by product type, 1997 - 2008
13. Percentage of all deals with some financial information, 1997 - 2008
14. Percentage of drug delivery deals with some financial information, 1997 - 2008
15. Integrated valuation methods
16. Ideal benchmarking deal cluster
17. Example pharmaceutical deal force field
18. Attrition by therapeutic area
19. Success rates for life cycle management projects
20. Pharmaceutical product decision tree
21. Enhanced revenues due to drug delivery system
22. Enhancement of patent life
23. Drug delivery alliance development process